D18

• UNSPSC Description:

  D18 is an immune modulator. D18 acts as a TLR7/8 dual agonist (EC50=24 nM for hTLR7 and 10 nM for hTLR8, respectively). D18 increases PD-L1 expression through epigenetic regulation, thus sensitizing tumors to PD-1/PD-L1 blockade. D18 is a ADC cytotoxin uesd for the systhesis of ADC HE-S2[1].

• Target Antigen:

  PD-1/PD-L1; Toll-like Receptor (TLR)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/d18.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  NC(N=C1NCCCC)=NC(C1=N2)=CC=C2CC(C=C3)=CC=C3CN(C)C

• Molecular Weight:

  364.49

• References & Citations:

  [1]He L, et al. Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. J Med Chem. 2021;64(21):15716-15726.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2230218-36-5